Conclusions
DM, diabetic
Metformin is recommended as first line therapy in patients with type 2 DM and is one of the most common drugs assumed by patients scheduled for coronary angiography. The present study expands the limited evidence on the safety of metformin continuation in patients undergoing coronary angiography and PCI. The main findings of our study are as follows:In diabetic patients without high-risk features for metformin accumulation, metformin continuation before and after coronary angiography with or without PCI resulted in similar preprocedural and 72-h lactate levels.The risk of CA-AKI was low, and no patients required hemodialysis during the index hospitalization or at mid-term follow-up.